Skin rejuvenation procedures are increasing in popularity, especially nonsurgical treatments such as dermal filler injections.
We are developing an rhCollagen-based photocurable regenerative dermal and soft filler comprised of rhCollagen and other substances which is intended to provide several revolutionary effects: lifting, sculpturing ability, retention to the host tissue, and tissue regeneration.
The photocurable regenerative filler is intended for injection in a semiliquid phase and hardened in-situ post injection by light illumination through the skin. Utilization of photocuring technology is expected to ease the injection process, particularly in subcutaneous and supraperiosteal applications.
As the product degrades, a newly formed tissue is expected to regenerate and take its place.
In February 2021, we entered into a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company.
The photocurable dermal filler is under development and is not commercially available.